Errata (DOI:10.1016/S1470-2045(06)70867-1);Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

Lancet Oncology

Volumn 7, Issue 10, 2006, Pages 813-820

  Gajjar, Amar ^a   Chintagumpala, Murali ^b   Ashley, David ^d   Kellie, Stewart ^c   Kun, Larry E ^a   Merchant, Thomas E ^a   Woo, Shaio ^b   Wheeler, Greg ^d   Ahern, Valerie ^c   Krasin, Matthew J ^a   Fouladi, Maryam ^a   Broniscer, Alberto ^a   Krance, Robert ^b   Hale, Gregory A ^a   Stewart, Clinton F ^a   Dauser, Robert ^b   Sanford, Robert A ^a   Fuller, Christine ^a   Lau, Ching ^b   Boyett, James M ^a   Wallace, Dana ^a   Gilbertson, Richard J ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIFOSTINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; MESNA; PENTETATE TECHNETIUM TC 99M; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METASTASIS; MULTICENTER STUDY; NERVE FIBER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION; STOMATITIS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT PLANNING; TUMOR CLASSIFICATION; TUMOR VOLUME;

EID: 33749044182     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70881-6     Document Type: Erratum

References (33)

1. Hughes E., Shilito J., Sallan S., et al. Medulloblastoma at the Joint Center for Radiation Therapy between 1968 and 1984: the influence of radiation dose and pattern of failure. Cancer 61 (1988) 1992-1998
2. Gottardo N., and Gajjar A. Current therapy for medulloblastoma. Curr Treat Options Neurol 8 (2006) 319-334
3. Zeltzer P., Boyett J., Finlay J., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (1999) 832-845
4. Taylor R., Bailey C., Robinson K., et al. Outcome of patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41 (2005) 727-734
5. Kortmann R., Kuhl J., Timmermann L., et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT 91. Int J Radiat Oncol Biol Phys 46 (2000) 269-279
6. Finaly J., Goldman S., Wong M., et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors: the Children's Cancer Study Group. J Clin Oncol 14 (1996) 2495-2503
7. Graham M., Herndon II J., Casey J., et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 15 (1997) 1814-1823
8. Dunkel I., Boyett J., Yates A., et al. High-dose carboplatin, thiotepa and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma: Children's Cancer Group. J Clin Oncol 16 (1998) 222-228
9. Gururangan S., Dunkel I., Goldman S., et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent brain tumors. J Clin Oncol 16 (1998) 2486-2493
10. Mahoney D., Strother D., Camitta B., et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent progressive malignant brain tumors in children. A pilot Pediatric Oncology Group study. J Clin Oncol 14 (1996) 382-388
11. Abrahemsen T., Lange B., Packer R., et al. A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors. J Pediatr Hematol Oncol 17 (1995) 134-139
12. Lachance D., Oette D., Schold Jr. S., et al. Dose escalation trial of cyclophosphamide with saragamostim in the treatment of central nervous system (CNS) neoplasms. Med Pediatr Oncol 24 (1995) 241-247
13. Frei III E., and Canellos G. Dose a critical factor in cancer chemotherapy. Am J Med 69 (1980) 585-594
14. Strother D., Ashley D., Kellie S., et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative trial. J Clin Oncol 19 (2001) 2696-2704
15. Chang C., Housepain E., and Herbert C. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastoma. Radiology 93 (1969) 1351-1359
16. Thompson M., Fuller C., Hogg T., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24 (2006) 1924-1931
17. Stewart C., Iacono L., Chintagumpala M., et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 22 (2004) 3357-3365
18. Kleihues P., and Cavanee W. World Health Organization classification of tumours: pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon, France
19. National Cancer Institute. Common toxicity criteria v2.0 (April 30, 1999). http://ctep.cancer.gov/reporting/ctc.html (accessed Aug 26, 2006)
20. Heideman R., Kovnar E., Kellie S., et al. Preirradiation chemotherapy with Carboplatin and Etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 13 (1995) 2247-2254
21. Peto R., Pike M., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: analyses and examples. Br J Cancer 35 (1977) 1-39
22. Packer R., Goldwein J., Nicholson H., et al. Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy. A Children's Cancer Group Study. J Clin Oncol 17 (1999) 2127-2136
23. Packer R., Gajjar A., Vezina G., et al. Phase III prospective randomized study of craniospinal radiation therapy followed by one of two adjuvant chemotherapy regimens for newly-diagnosed average risk medulloblastoma. J Clin Oncol 24 (2006) 4202-4208
24. Miralbell R., Fitzgerald T., Laurie F., et al. Radiotherapy in pediatric medulloblastoma: quality assessment of pediatric oncology group trial 9031. Int J Radiat Oncol Biol Phys 64 (2006) 1325-1330
25. Oyharcabal-Bourden V., Khalifa C., Gentet J., et al. Standard-risk medulloblastoma treated with adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 23 (2005) 4726-4734
26. 1) medulloblastoma. The SIOP/UKCCSG PNET-3 study. J Clin Oncol 21 (2003) 1581-1591
27. Vassal G., Tranchand B., Valteau-Couanet D., et al. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with Neuroblastoma and medulloblastoma. Bone Marrow Transplant 27 (2001) 471-477
28. Dupuis-Girod S., Hartmann O., Benhamou E., et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?. J Neuroonocol 27 (1996) 87-98
29. McManamy C., Lamont J., Taylor R., et al. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastoma. J Neuropathol Exp Neurol 62 (2003) 627-632
30. Gilbertson R. Medulloblastoma: signalling a change in treatment. Lancet Oncol 5 (2004) 209-218
31. Ellison D., Onilude O., Lindsey J., et al. β catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumor Committee. J Clin Oncol 23 (2005) 7951-7957
32. Mulhern R., Merchant T., Gajjar A., et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5 (2004) 399-408
33. Fouladi M., Chintagumpala M., Laningham F., et al. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 22 (2004) 4551-4560